Dataset Information

Calycosin as a novel PI3K activator reduces inflammation and fibrosis in heart failure through AKT-IKK/STAT3 axis

ABSTRACT: Aim: Inflammation and fibrosis have been shown to be critical factors in heart failure (HF) progression. Calycosin (Cal) is the major active component of Radix astragali and has been widely used to treat inflammation in clinical practice. However, whether Cal could ameliorate myocardial infarction (MI)-induced inflammation and fibrosis and precise mechanisms remain uncertain. The aim of this study is to explore the role of Cal in HF and to clarify the underlying mechanisms. Methods: For in vivo experiments, rats underwent left anterior descending (LAD) artery ligation for HF model, and the cardioprotective effects of Cal were measured by echocardiographic assessment and histological examination. RNA-seq approach was applied to explore potential differential genes and pathways. For further mechanistic study, pro-inflammatory conditioned media (CM)-induced H9C2 cells injury model and TGFβ-stimulated cardiac fibroblasts model were applied to determine the regulatory mechanisms of Cal. Results: In vivo experiment, echocardiography results showed that Cal significantly improved heart function. GO and Reactome enrichment revealed that inflammation and fibrosis pathway are involved in Cal-treated group. KEGG enrichment indicated that PI3K-AKT pathway is enriched in the Cal-treated group. Further experiments proved that Cal alleviated cardiomyocyte inflammatory responses evidenced by down-regulating the expressions of phosphorylated IκB kinase α/β (p-IKKα/β), phosphorylated nuclear factor kapa B (p-NFκB) and tumor necrosis factor α (TNFα). Besides, Cal effectively attenuated cardiac fibrosis through the inhibitions of expressions and depositions of collagen I and collagen III. In vitro experiments, the phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002 could abrogate the anti-inflammation and anti-fibrosis therapeutic effects of Cal, demonstrating that the cardio-protective effects of Cal were mediated through upregulations of PI3K and serine/threonine kinase (AKT). Conclusion: Cal improves cardiac function against HF by inhibiting cardiomyocytes inflammation and fibroblasts fibrosis via activation of the PI3K-AKT pathway.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE184649 | GEO | 2021/09/27

REPOSITORIES: GEO

ACCESS DATA

Similar Datasets

Project description:Heart failure (HF), a major health concern worldwide, with high morbidity and mortality, renders the urgent need for new treatments. Lingguizhugan decoction (LD), a classic Chinese formula, has been clinically used to treat HF. However, the molecular mechanisms involved are not fully elucidated. In this study, we first used the experimental model of transverse aortic constriction (TAC)-induced HF in C57BL/6J mice to evaluate the therapeutic efficacy of LD. Our results showed that LD exerted protective effects against TAC-induced HF by alleviating cardiac dysfunction and cardiac dilation, which might be associated with LD’s effects on down-regulating CH-related gene and protein expression. To further reveal the potential molecular mechanisms of LD in the treatment of HF, we utilized the network pharmacology to predict the core targets and potential pathways and further utilized the transcriptomics to provide changed gene profile in the heart tissue. Our results suggested that cardiac hypertrophy signaling including AKT and MAPKs signaling pathways were significantly enriched, indicating that these pathways may be the major regulatory for LD on HF treatment. Furthermore, the protein levels in AKT-GSK3β/mTOR and MAPKs pathway were determined in both compensated and decompensated states. LD inhibited the MAPKs activation, especially, reducing phosphorylated levels of p38 from the compensated state and phosphorylated levels of ERK from the decompensated state, and the latter might depend on the regulation of AMPK by LD. Moreover, LD exerts a dual role in regulating AKT-GSK3β/mTOR/P70S6K signaling pathway, characterized by active effects in the compensated state, and inhibitory effects in the decompensated state. The regulatory effect of LD on mTOR might rely on activating AKT in the compensatory state, while might be jointly determined by AKT and AMPKαin the decompensated state. Finally, by using UPLC-QE-MS/MS analysis, we detected 62 compounds in LD extract, and found 19 of which were detected in plasma of rats. Among them, 17 bioactive compounds likely regulate AKT-GSK3β/mTOR and MAPKs signaling pathway by using bioinformatics prediction. Taken together, our study showed that LD did have a better therapeutic effect on HF via dynamically balancing AKT-GSK3β/mTOR/P70S6K pathway and MAPKs pathway. Moreover, our study also provides possible bioactive compounds responsible for LD treatment on HF.

Dataset Information

Calycosin as a novel PI3K activator reduces inflammation and fibrosis in heart failure through AKT-IKK/STAT3 axis

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure